Temozolomide
- PDF / 169,404 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 52 Downloads / 140 Views
1 S
Hypersensitivity reaction: 15 case reports In an observational study, 15 patients (9 women and 6 men) aged 26.8–64.7 years were described, who developed hypersensitivity reactions, while receiving temozolomide for gliomas [routes not stated]. The patients with gliomas (Oligodendroglioma/Diffuse astrocytoma/Anaplastic astrocytoma/Glioblastoma), started receiving temozolomide 75 mg/m2. From 0.6–88.4 days of temozolomide initiation, the patients developed hypersensitivity reaction with symptoms of hives, non-urticarial rash, leg oedema or measles like rash. In thirteen of the 15 patients, temozolomide was withdrawn at 1–60 days of hypersensitivity onset. In the remaining two patients, temozolomide was withdrawn on the same day of hypersensitivity onset. After 0.5–111.7 months of hypersensitivity onset, the patients underwent desensitisation with metronomic dosing of temozolomide. In eleven of the 15 patients, no further recurrence of hypersensitivity was noted. Neth BJ, et al. Temozolomide desensitization followed by metronomic dosing in patients with hypersensitivity. Cancer Chemotherapy and Pharmacology 86: 375-382, No. 3, 803505713 Sep 2020. Available from: URL: http://doi.org/10.1007/s00280-020-04123-y
0114-9954/20/1825-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 10 Oct 2020 No. 1825
Data Loading...
